• Alvarez F, Brache V, Fernández E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril. 1988;49(5):768-773.
  • American College of Obstetricians and Gynecologists. ACOG Educational Bulletin. Breastfeeding: maternal and infant aspects. Number 258, July 2000. Int J Gynecol Obstet. 2001;74(2):217-232.
  • Arancibia V, Peña C, Allen HE, Lagos G. Characterization of copper in uterine fluids of patients who use the copper T-380A intrauterine device. Clin Chim Acta. 2003;332(1-2):69-78.
  • Association of Reproductive Health Professionals (ARHP) Web site. Choosing a Birth Control Method. http://www.arhp.org/Publications-and-Resources/Patient-Resources/Interactive-Tools/Choosing-a-Birth-Control-Method. Accessed November 17, 2008.
  • Association of Women's Health, Obstetric and Neonatal Nurses. Female OB/GYNs speak out about health practices. AWHONN Lifelines. 2004;8(1):14-18.
  • Data on file. Duramed Pharmaceuticals, Inc., Pomona, NY.
  • Hillis SD, Marchbanks PA, Tylor LR, Peterson HB; for the U.S. Collaborative Review of Sterilization Working Group. Poststerilization regret: findings from the United States collaborative review of sterilization. Obstet Gynecol. 1999;93(6):889-895.
  • Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility—follow-up after participation in a randomized clinical trial. Contraception. 2007;75(2):88-92.
  • Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med.
    2001;345(8):561-567.
  • Mircette [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc; 2005.
  • Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2008.
  • Mosher WD, Martinez GM, Chandra A, Abma HC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data. 2004;350:1-36.
  • Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 µg/d and the Copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. Fertil Steril. 1994;61(1):70-77.
  • Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 1992;166(4):1208-1213.
  • Trussell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health. 1995;85(4):494-503.
  • Vessey MP, Lawless M, McPherson K, Yeates D. Fertility after stopping use of intrauterine contraceptive device. Br Med J. 1983;286(6359):106.
  • World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva, Switzerland: World Health Organization, Reproductive Health and Research; 2004.

ParaGard® does not protect against HIV/AIDS or other sexually transmitted infections. ParaGard® must not be used by women who are or may be pregnant; have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk for PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection in the cervix; have an allergy to any component; or have Wilson's disease. The most common side effects of ParaGard® are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months. If a woman misses her period, she must be promptly evaluated for pregnancy. Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard®, are PID, perforation of the uterus, and expulsion.